Mindwalk Holdings Corp (HYFT) Stock Price, Quote & News

Company Profile

MindWalk Holdings Corp. operates as a bio-native AI company. It focuses on the integration of artificial intelligence, multi-omics data, and advanced laboratory research to accelerate the discovery and development of biologics. The company, through its LensAI platform and HYFT technology, it partners with pharmaceutical and biotechnology companies to drive de-risk drug development and unlock therapeutic possibilities. The company was formerly known as ImmunoPrecise Antibodies Ltd. and changed it...

Industry: Biotechnology

Sector: Healthcare

Phone: 800 620 4187

Website: www.mindwalkai.com

Address:

Industrious 823 Congress Ave, Suite 300, Austin, United States

DiamondHandsHarold Dec. 5 at 10:12 PM

$HYFT is using AI to accelerate drug discovery in a space that’s getting a ton of attention right now. Early but the tech angle gives it real momentum potential.

0 · Reply

Rcbremen88 Dec. 5 at 6:40 PM

$HYFT if we make a new high get ready for a short squeeze 2.12

0 · Reply

NyseDayTrader Dec. 5 at 2:08 AM

$HYFT mindwalk: faster,better,cheaper !

0 · Reply

DiamondHandsHarold Dec. 5 at 1:21 AM

$HYFT is using AI to speed up drug discovery in a space that’s getting a ton of attention right now. Early but the tech angle gives it real momentum potential.

0 · Reply

NyseDayTrader Dec. 4 at 9:59 PM

$HYFT Frederic basically told you why mindwalk will succeed. Patents! They’re the only company in the world with hyft technology patents(25+)

0 · Reply

NyseDayTrader Dec. 4 at 8:44 PM

$HYFT Frederic tells investors one of the most important things to look for in AI investments is patents. Mindwalk holds 25+ granted patents

1 · Reply

NyseDayTrader Dec. 4 at 5:58 PM

$HYFT Todays value add from Frederic... PATENTS! They have over 25 GRANTED

0 · Reply

Rcbremen88 Dec. 4 at 4:52 PM

$HYFT Come on 3

0 · Reply

NyseDayTrader Dec. 4 at 3:53 PM

$HYFT Almost time..

0 · Reply

calderinho Dec. 4 at 12:42 PM

$HYFT $ROBO.CSE $XBOTF

0 · Reply

MindWalk CTO Dr. Dirk Van Hyfte to Join Fireside Chat at AI Drug Discovery & Development Summit 2025

Oct 21, 2025, 8:28 AM EDT - 6 weeks ago

MindWalk Appoints R. Scott Areglado as Chief Financial Officer to Strengthen Financial Leadership and Support Growth Strategy

Oct 17, 2025, 8:18 AM EDT - 7 weeks ago

MindWalk Holdings: Repositioned TechBio Platform With Early LensAI Proof Points

Oct 15, 2025, 7:00 AM EDT - 7 weeks ago

MindWalk Appoints Dr. Thomas W. Lynch as Chief Business Officer to Accelerate Commercial Expansion

Oct 9, 2025, 2:26 PM EDT - 2 months ago

MindWalk Holdings Corp. (HYFT) ImmunoPrecise Antibodies Ltd. - Shareholder/Analyst Call Prepared Remarks Transcript

Oct 9, 2025, 7:00 AM EDT - 2 months ago

MindWalk Announces Share Repurchase Program

Sep 22, 2025, 7:02 AM EDT - 2 months ago

MindWalk Advances AI-Designed GLP-1 Program with First-in-Class Dual-Pathway Regimen for Aging and Longevity

Sep 15, 2025, 12:58 PM EDT - 2 months ago

MindWalk Holdings Corp. (HYFT) Q1 2026 Earnings Call Transcript

Sep 15, 2025, 8:44 AM EDT - 2 months ago

MindWalk Holdings Corp.™ (formerly ImmunoPrecise Antibodies™) Reports Record $7.6 Million Quarterly Revenue, 45% Growth, Margin Expansion, Narrowed Losses, and Strengthened Balance Sheet

Sep 3, 2025, 8:48 AM EDT - 3 months ago

ImmunoPrecise Rebrands as MindWalk, Announces NASDAQ Ticker Change to “HYFT”

Sep 2, 2025, 8:01 AM EDT - 3 months ago

ImmunoPrecise Antibodies to Participate at H.C. Wainwright's 27th Annual Global Investment Conference in New York

Aug 27, 2025, 8:22 AM EDT - 3 months ago

ImmunoPrecise Advances AI Discovered and Developed Universal Dengue Vaccine Initiative: Moves into Preclinical Antibody Generation

Aug 6, 2025, 8:00 AM EDT - 4 months ago

ImmunoPrecise Antibodies Ltd. Divests Netherlands Facilities to AVS Bio to Accelerate Bio-Native AI Innovation

Aug 6, 2025, 8:00 AM EDT - 4 months ago

AVS Bio, an Arlington Capital Partners Portfolio Company, Expands Antibody Discovery and Protein Production Capabilities With Acquisition of ImmunoPrecise Antibodies Europe From ImmunoPrecise Antibodies Ltd.

Aug 4, 2025, 7:00 PM EDT - 4 months ago

ImmunoPrecise (IPA) Q4 2025 Earnings Transcript

Jul 29, 2025, 12:39 PM EDT - 4 months ago

ImmunoPrecise Antibodies Ltd. (IPA) Q4 2025 Earnings Conference Call Transcript

Jul 29, 2025, 8:28 AM EDT - 4 months ago

ImmunoPrecise Antibodies (IPA) Reports Full Fiscal Year 2025 Results, Record Fourth Quarter Revenue, and Record Fourth Quarter Adjusted EBITDA

Jul 24, 2025, 8:22 AM EDT - 4 months ago

ImmunoPrecise Releases New Findings Showing LENSai™ Quickly Flags Anti-Drug-Antibody Risk—Long Before the Clinic

Jul 21, 2025, 8:28 AM EDT - 4 months ago

ImmunoPrecise Appoints Healthcare Data Visionary Jeff Fried to Advisory Board

Jul 16, 2025, 8:05 AM EDT - 5 months ago

IPA to Report Financial Results and Recent Business Highlights for Fourth Quarter and Full Fiscal Year 2025 on July 29, 2025

Jul 14, 2025, 8:01 AM EDT - 5 months ago

ImmunoPrecise Regains Compliance with Nasdaq Minimum Bid Price Requirement

Jul 7, 2025, 9:00 AM EDT - 5 months ago

ImmunoPrecise Antibodies Appoints Industry Veteran Jon Lieber to Board of Directors

Jul 3, 2025, 8:19 AM EDT - 5 months ago

ImmunoPrecise Validates LENSai Epitope Mapping Platform Across Broad Range of Unseen Therapeutic Targets Beyond Training Data

Jun 24, 2025, 7:02 AM EDT - 5 months ago

ImmunoPrecise Advances Universal Dengue Vaccine, Confirming Safety, Immune Activation, and Structural Stability Using its LENSai™ Platform Powered by Patented HYFT® Technology

Jun 12, 2025, 8:01 AM EDT - 6 months ago

AI-Designed GLP-1 Peptides from ImmunoPrecise Antibodies Surpass Semaglutide in Receptor Activation Studies

Jun 5, 2025, 8:01 AM EDT - 6 months ago

ImmunoPrecise Announces AI-Driven Breakthrough in Universal Dengue Vaccine Discovery

AMD

May 21, 2025, 8:49 AM EDT - 7 months ago

ImmunoPrecise Antibodies Engages CORE IR to Enhance Investor Engagement Efforts

May 20, 2025, 8:28 AM EDT - 7 months ago

ImmunoPrecise Antibodies (IPA) to Present at Maxim Group's 2025 Virtual Tech Conference

May 12, 2025, 8:01 AM EDT - 7 months ago

IPA's LENSai™ Platform Delivers X-Ray–Level Epitope Mapping Insights in Hours, Matching Gold-Standard Methods with Greater Speed

AMD

Apr 11, 2025, 8:40 AM EDT - 8 months ago

ImmunoPrecise Antibodies Highlights Alignment of Proprietary AI-Driven Platform LENSai™ with FDA's Shift to Non-Animal Testing Methods

Mar 28, 2025, 12:59 PM EDT - 9 months ago

ImmunoPrecise Antibodies Ltd. (IPA) Q3 2025 Earnings Call Transcript

Mar 28, 2025, 8:01 AM EDT - 9 months ago

ImmunoPrecise Antibodies (IPA) Reports Financial Results and Recent Business Highlights for Third Quarter Fiscal Year 2025

Mar 13, 2025, 7:02 AM EDT - 9 months ago

ImmunoPrecise Antibodies and a Global Biotechnology Leader Enter into a USD $8M-$10M Partnership for the Development of Novel Cancer Therapeutics.

Mar 11, 2025, 10:17 PM EDT - 9 months ago

IPA to Reschedule Financial Results and Recent Business Highlights for Third Quarter Fiscal Year 2025 on March 28, 2025

Mar 5, 2025, 8:01 AM EST - 9 months ago

IPA to Report Financial Results and Recent Business Highlights for Third Quarter Fiscal Year 2025 on March 13, 2025

Feb 26, 2025, 8:01 AM EST - 10 months ago

IPA and RIBOPRO Partner to Advance mRNA-Driven Antibody Discovery, Unlocking New Frontiers in Immunotherapy

Feb 24, 2025, 8:01 AM EST - 10 months ago

ImmunoPrecise Antibodies Announces Key Leadership Changes

Feb 20, 2025, 8:01 AM EST - 10 months ago

ImmunoPrecise Antibodies Announces Transfer to Nasdaq Capital Market and Extension of Bid Price Compliance Period

Jan 27, 2025, 8:01 AM EST - 11 months ago

ImmunoPrecise Antibodies (IPA) Announces Completion of At-the-Market Equity Offering and Full Conversion of Yorkville Debenture

Jan 22, 2025, 7:02 AM EST - 11 months ago

IPA (ImmunoPrecise Antibodies) Pioneers AI-Designed GLP-1 Therapies: A Potential New Chapter in Diabetes Treatment

Jan 17, 2025, 8:01 AM EST - 11 months ago

ImmunoPrecise Antibodies Realigns Pipeline Strategy, Empowering Drug Discovery with AI and First-Principles Innovation

Dec 31, 2024, 7:56 PM EST - 1 year ago

IPA Announces Resignation of Chief Financial Officer

Dec 30, 2024, 10:03 PM EST - 1 year ago

$116 Million Multifamily Asset Sale in Central California Coast Region Brokered by Marcus & Millichap's Institutional Property Advisors

MMI

Dec 23, 2024, 8:30 AM EST - 1 year ago

ImmunoPrecise Antibodies (IPA) Demonstrates Strong Market Confidence with Insider Share Purchases

Dec 19, 2024, 10:15 AM EST - 1 year ago

IPA to Present at The Microcap Conference 2025

Dec 10, 2024, 5:33 PM EST - 1 year ago

ImmunoPrecise Antibodies Ltd. (IPA) Q2 2025 Earnings Call Transcript

Dec 10, 2024, 8:30 AM EST - 1 year ago

ImmunoPrecise Antibodies (IPA) Reports Financial Results and Recent Business Highlights for Second Quarter Fiscal Year 2025

Dec 4, 2024, 8:00 AM EST - 1 year ago

IPA to Present at The Benchmark Company's Upcoming Discovery One-on-One Investor Conference

Dec 3, 2024, 8:30 AM EST - 1 year ago

IPA to Report Financial Results and Recent Business Highlights for Second Quarter Fiscal Year 2025 on December 10, 2024

Nov 13, 2024, 9:00 AM EST - 1 year ago

$20 Billion Market Breakthrough: IPA Pioneers High-Impact Antibody Development for Next-Generation ADC Cancer Therapies

DiamondHandsHarold Dec. 5 at 10:12 PM

$HYFT is using AI to accelerate drug discovery in a space that’s getting a ton of attention right now. Early but the tech angle gives it real momentum potential.

0 · Reply

Rcbremen88 Dec. 5 at 6:40 PM

$HYFT if we make a new high get ready for a short squeeze 2.12

0 · Reply

NyseDayTrader Dec. 5 at 2:08 AM

$HYFT mindwalk: faster,better,cheaper !

0 · Reply

DiamondHandsHarold Dec. 5 at 1:21 AM

$HYFT is using AI to speed up drug discovery in a space that’s getting a ton of attention right now. Early but the tech angle gives it real momentum potential.

0 · Reply

NyseDayTrader Dec. 4 at 9:59 PM

$HYFT Frederic basically told you why mindwalk will succeed. Patents! They’re the only company in the world with hyft technology patents(25+)

0 · Reply

NyseDayTrader Dec. 4 at 8:44 PM

$HYFT Frederic tells investors one of the most important things to look for in AI investments is patents. Mindwalk holds 25+ granted patents

1 · Reply

NyseDayTrader Dec. 4 at 5:58 PM

$HYFT Todays value add from Frederic... PATENTS! They have over 25 GRANTED

0 · Reply

Rcbremen88 Dec. 4 at 4:52 PM

$HYFT Come on 3

0 · Reply

NyseDayTrader Dec. 4 at 3:53 PM

$HYFT Almost time..

0 · Reply

calderinho Dec. 4 at 12:42 PM

$HYFT $ROBO.CSE $XBOTF

0 · Reply

harrijakey Dec. 4 at 12:34 PM

$HYFT $ROBO.CSE $XBOTF

0 · Reply

NyseDayTrader Dec. 4 at 2:25 AM

$HYFT $ROBO.CSE $XBOTF

0 · Reply

DiamondHandsHarold Dec. 4 at 1:08 AM

$HYFT is using AI to speed up and improve drug discovery, a space getting a lot of attention right now. Early but the tech angle gives it strong momentum potential.

0 · Reply

stocks_2watch Dec. 3 at 3:41 PM

$HYFT, $ROBO.CSE , $XBOTF , all have an important, informative upcoming Webinar, sign up and Details here: https://globalonemedia.zoom.us/webinar/register/WN_jKsJnslPQd2unBG6QWVDNQ#/registration

0 · Reply

Samuelstark Dec. 3 at 2:11 PM

$HYFT

0 · Reply

Risk1123 Dec. 2 at 9:01 PM

$HYFT

0 · Reply

windswept Dec. 2 at 7:48 PM

$HYFT

0 · Reply

NyseDayTrader Dec. 2 at 4:47 PM

$HYFT well Bath? Been very quiet lately. Over your head again?

0 · Reply

KiingDrew Dec. 2 at 2:29 PM

$HYFT showing growth, not just promises

0 · Reply

Tunes444 Dec. 1 at 8:59 PM

$HYFT

0 · Reply

MOMOdough Nov. 29 at 6:12 AM

$HYFT I think we will see a 10x from here by end of Q1 2026.

4 · Reply

kozyman87 Nov. 28 at 10:25 PM

$HYFT https://ai.northeastern.edu/news/making-data-work Our newest addition to team $HYFT will be working with Pharma/Biotech /tech and Hospitals Development of our business partners into cash and deals

0 · Reply

Market Cap	86.31M
Revenue (ttm)	17.59M
Net Income (ttm)	-21.69M
EPS (ttm)	N/A
PE Ratio	0.00
Forward PE	N/A
Profit Margin	-123.31%
Debt to Equity Ratio	0.00

Volume	284,300
Avg Vol	472,320
Day's Range	N/A - N/A
Shares Out	46.16M
Stochastic %K	84%
Beta	0.47
Analysts	Sell
Price Target	$4.00